BR112023022999A2 - Fusões peptídeo-fc para tratar distúrbios amiloides - Google Patents

Fusões peptídeo-fc para tratar distúrbios amiloides

Info

Publication number
BR112023022999A2
BR112023022999A2 BR112023022999A BR112023022999A BR112023022999A2 BR 112023022999 A2 BR112023022999 A2 BR 112023022999A2 BR 112023022999 A BR112023022999 A BR 112023022999A BR 112023022999 A BR112023022999 A BR 112023022999A BR 112023022999 A2 BR112023022999 A2 BR 112023022999A2
Authority
BR
Brazil
Prior art keywords
amyloid
peptide
fusions
reactive peptide
amyloid disorders
Prior art date
Application number
BR112023022999A
Other languages
English (en)
Inventor
S Foster James
Jaume Pons
S Wall Jonathan
Original Assignee
Attralus Inc
Univ Tennessee Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attralus Inc, Univ Tennessee Res Found filed Critical Attralus Inc
Publication of BR112023022999A2 publication Critical patent/BR112023022999A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

fusões peptídeo-fc para tratar dis- túrbios amiloides. a presente invenção refere-se a proteínas de fusão peptídeo-fc reativas a amiloide compreendendo um peptídeo reativo a amiloide ligado a uma região fc humana. também são fornecidos neste documento métodos para tratar doenças à base de amiloide e identificar depósitos de amiloide administrando uma proteína de fusão peptídeo-fc reativa a amiloide compreendendo um peptídeo reativo a amiloide ligado a uma região fc humana.
BR112023022999A 2021-05-05 2022-05-04 Fusões peptídeo-fc para tratar distúrbios amiloides BR112023022999A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184682P 2021-05-05 2021-05-05
US202163186605P 2021-05-10 2021-05-10
PCT/US2022/072112 WO2022236286A1 (en) 2021-05-05 2022-05-04 Peptide-fc fusions for treating amyloid disorders

Publications (1)

Publication Number Publication Date
BR112023022999A2 true BR112023022999A2 (pt) 2024-02-15

Family

ID=83932449

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022999A BR112023022999A2 (pt) 2021-05-05 2022-05-04 Fusões peptídeo-fc para tratar distúrbios amiloides

Country Status (6)

Country Link
EP (1) EP4333871A1 (pt)
AU (1) AU2022271333A1 (pt)
BR (1) BR112023022999A2 (pt)
CA (1) CA3217756A1 (pt)
IL (1) IL308004A (pt)
WO (1) WO2022236286A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213506B2 (en) * 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
CA3052058A1 (en) * 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
AU2019207735A1 (en) * 2018-01-10 2020-07-23 Denali Therapeutics Inc. Transferrin receptor-binding polypeptides and uses thereof
US20220411489A1 (en) * 2019-11-15 2022-12-29 Attralus, Inc. Modified immunoglobulins for targeting amyloid deposits

Also Published As

Publication number Publication date
CA3217756A1 (en) 2022-11-10
WO2022236286A1 (en) 2022-11-10
IL308004A (en) 2023-12-01
AU2022271333A9 (en) 2023-11-16
EP4333871A1 (en) 2024-03-13
AU2022271333A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA202090776A1 (ru) Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
BR112022009273A2 (pt) Imunoglobulinas modificadas para direcionar depósitos amiloides
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
BR112018016281A2 (pt) molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
CR20190276A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
EA202190669A1 (ru) Процесс получения вакцинной композиции
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
BR112017008525A2 (pt) proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo.
PE20180251A1 (es) PROTEINA DE UNIION A RGMa Y SU USO
Subramanian et al. Passive immunization targeting the N-terminal region of phosphorylated tau (residues 68–71) improves spatial memory in okadaic acid induced tauopathy model rats
EA202092459A1 (ru) Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
AR101735A1 (es) Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro)
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
PE20210111A1 (es) Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
EA202192460A1 (ru) Синтетические нейромодуляторные пептиды
BR112021020777A2 (pt) Vacina de subunidade do csfv
BR112023022999A2 (pt) Fusões peptídeo-fc para tratar distúrbios amiloides
PE20210419A1 (es) Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
EA202192488A1 (ru) Антитела против tsg-6 и их применения
UY39036A (es) Factores de transcripción de proteína de dedos de zinc para represión de la expresión tau